Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Combination immunotherapy for advanced lung cancer.

S C Yang1, E A Grimm, J A Roth

  • 1Department of General Surgery, University of Texas Health Science Center, Houston.

Journal of the National Cancer Institute. Monographs
|January 1, 1992
PubMed
Summary

This study explored using low-dose interleukin 2 with other biologic agents to activate the immune system in advanced non-small-cell lung cancer (NSCLC) patients. These immunotherapeutic strategies offer potential new treatment options for NSCLC.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The single-cell assay in cell-mediated cytotoxicity.

Immunology today·2014
Same author

Regulation of iNOS by the p44/42 mitogen-activated protein kinase pathway in human melanoma.

Oncogene·2006
Same author

Autoimmunity and hypothyroidism in patients with uveal melanoma.

Melanoma research·2001
Same author

Down-regulated melanoma differentiation associated gene (mda-7) expression in human melanomas.

International journal of cancer·2001
Same author

Decreased non-MHC-restricted (CD56+) killer cell cytotoxicity after spaceflight.

Journal of applied physiology (Bethesda, Md. : 1985)·2001
Same author

A novel preclinical model of human malignant melanoma utilizing bioreactor rotating-wall vessels.

In vitro cellular & developmental biology. Animal·2001

Area of Science:

  • Immunology
  • Oncology
  • Pharmacology

Background:

  • Cytokine-based therapies are under-investigated for advanced non-small-cell lung cancer (NSCLC).
  • Activating the endogenous immune system is a key goal in cancer treatment.
  • Biological agents offer potential for immunotherapeutic manipulation.

Purpose of the Study:

  • To investigate effective immunotherapeutic strategies for advanced NSCLC.
  • To explore the use of low-dose interleukin 2 (IL-2) in combination with other biologic agents.
  • To activate the host's immune system against NSCLC.

Main Methods:

  • Development of a basic laboratory and clinical research program.
  • Utilizing low-dose interleukin 2 (IL-2).
  • Administering other biologic response modifiers in conjunction with IL-2.

Related Experiment Videos

Main Results:

  • Summarizes research efforts in applying these immunotherapeutic manipulations.
  • Focuses on the combination of low-dose IL-2 and biologic response modifiers.
  • Highlights the investigation into activating endogenous immunity for NSCLC treatment.

Conclusions:

  • Low-dose interleukin 2 combined with biologic response modifiers represents a potential therapeutic avenue for advanced NSCLC.
  • Further research into immunotherapeutic manipulations is warranted for NSCLC.
  • Activating the endogenous immune system is a promising strategy for treating non-small-cell lung cancer.